By Pharmaceutical Technology
Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn.
The acquisition was concluded through a tender offer and subsequent merger of ARIAD with Takeda Pharmaceuticals USA’s wholly owned subsidiary Kiku Merger.
Following the acquisition, ARIAD is now an indirect wholly owned subsidiary of Takeda.
Takeda Pharmaceutical Company president and CEO Christophe Weber said: “The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area.